TY - JOUR
T1 - Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization
AU - Mansour, Ahmad M.
AU - Mackensen, Friederike
AU - Arevalo, J. Fernando
AU - Ziemssen, Focke
AU - Mahendradas, Padmamalini
AU - Mehio-Sibai, Abla
AU - Hrisomalos, Nicholas
AU - Lai, Timothy Y.Y.
AU - Dodwell, David
AU - Chan, Wai Man
AU - Ness, Thomas
AU - Banker, Alay S.
AU - Pai, Sivakami A.
AU - Berrocal, Maria H.
AU - Tohme, Rania
AU - Heiligenhaus, Arnd
AU - Bashshur, Ziad F.
AU - Khairallah, Moncef
AU - Salem, Khalil M.
AU - Hrisomalos, Frank N.
AU - Wood, Matthew H.
AU - Heriot, Wilson
AU - Adan, Alfredo
AU - Kumar, Atul
AU - Lim, Lyndell
AU - Hall, Anthony
AU - Becker, Matthias
PY - 2008/9
Y1 - 2008/9
N2 - Purpose: To assess the role of bevacizumab in inflammatory ocular neovascularization. Design: Retrospective, multicenter, consecutive case series of inflammatory ocular neovascularization. Methods: Patients with inflammatory ocular neovascularization of varying causes for whom standard therapy failed were treated with intravitreal injection of bevacizumab. Main outcome measures included improvement of best-corrected visual acuity (BCVA) expressed in logarithm of minimum angle of resolution units, response of inflammatory ocular neovascularization by funduscopy and angiography, and decrease in central foveal thickness as measured by optical coherence tomography at the three-month follow-up. Results: At the three-month follow-up, 84 eyes of 79 patients had been treated with a mean of 1.3 injections (range, one to three). Thirty-four eyes showed juxtafoveal choroidal neovascularization (CNV), 34 eyes showed subfoveal CNV, eight eyes showed peripapillary CNV, and 11 eyes showed neovascularization of the disc (NVD) or neovascularization elsewhere (NVE). BCVA improved 2.4 lines from 0.68 (6/28 or 20/94) to 0.44 (6/17 or 20/55) (P < .001). BCVA improved by one to three lines in 34.5% of the eyes, by four to six lines in 16.7% of the eyes, and by more than six lines in 14.2% of the eyes. Function was unchanged in 23.8% of the eyes. BCVA worsened in 10.7% (zero to three lines in 7.1%, more than four lines in 3.6%). Central foveal thickness decreased from baseline 346 to 252 μm (P < .001). For CNV, 32 eyes (43.2%) had complete regression after the injection, 27 (36.5%) had partial regression, five (6.8%) had no response, and 10 eyes (13.5%) were not evaluated by the contributors. For NVD or NVE, seven eyes (63.6%) had complete regression of new vessels and four eyes (36.4%) had partial regression after the injection. Conclusions: Intravitreal bevacizumab led to short-term significant visual improvement and regression of inflammatory ocular neovascularization in a wide variety of inflammatory ocular diseases.
AB - Purpose: To assess the role of bevacizumab in inflammatory ocular neovascularization. Design: Retrospective, multicenter, consecutive case series of inflammatory ocular neovascularization. Methods: Patients with inflammatory ocular neovascularization of varying causes for whom standard therapy failed were treated with intravitreal injection of bevacizumab. Main outcome measures included improvement of best-corrected visual acuity (BCVA) expressed in logarithm of minimum angle of resolution units, response of inflammatory ocular neovascularization by funduscopy and angiography, and decrease in central foveal thickness as measured by optical coherence tomography at the three-month follow-up. Results: At the three-month follow-up, 84 eyes of 79 patients had been treated with a mean of 1.3 injections (range, one to three). Thirty-four eyes showed juxtafoveal choroidal neovascularization (CNV), 34 eyes showed subfoveal CNV, eight eyes showed peripapillary CNV, and 11 eyes showed neovascularization of the disc (NVD) or neovascularization elsewhere (NVE). BCVA improved 2.4 lines from 0.68 (6/28 or 20/94) to 0.44 (6/17 or 20/55) (P < .001). BCVA improved by one to three lines in 34.5% of the eyes, by four to six lines in 16.7% of the eyes, and by more than six lines in 14.2% of the eyes. Function was unchanged in 23.8% of the eyes. BCVA worsened in 10.7% (zero to three lines in 7.1%, more than four lines in 3.6%). Central foveal thickness decreased from baseline 346 to 252 μm (P < .001). For CNV, 32 eyes (43.2%) had complete regression after the injection, 27 (36.5%) had partial regression, five (6.8%) had no response, and 10 eyes (13.5%) were not evaluated by the contributors. For NVD or NVE, seven eyes (63.6%) had complete regression of new vessels and four eyes (36.4%) had partial regression after the injection. Conclusions: Intravitreal bevacizumab led to short-term significant visual improvement and regression of inflammatory ocular neovascularization in a wide variety of inflammatory ocular diseases.
UR - http://www.scopus.com/inward/record.url?scp=49949094774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49949094774&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2008.05.024
DO - 10.1016/j.ajo.2008.05.024
M3 - Article
C2 - 18619571
AN - SCOPUS:49949094774
SN - 0002-9394
VL - 146
SP - 410-416.e1
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 3
ER -